Content

### MilliporeSigma Single Molecule Counting (SMCxPRO® & Erenna®)

-   Cytokine analysis utilizing Single Molecule Counting technology enables sub-pg/ml sensitivity for accurate measurement of low abundance biomarkers in normal or disease sera/plasma
    
-   Minimal sample dilution requirement with 4-Log+ dynamic range
    
-   High precision cytokine immunoassays provide reproducible data
    
-   Extensive analyte menu of over 40 different cytokine assays covering several disease areas including IFN-γ, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-17F, IL-17 heterodimer, IL-23, GLP-1, and TNF-α
    
-   [See below for representative data](https://www.pblassaysci.com/cytokine-assay/SMC-service#Data)

Employing MilliporeSigma's **S**ingle **M**olecule **C**ounting (SMC) technology with robust microparticle-based SMCxPRO® & Erenna® immunoassays, PBL’s cytokine detection services can provide scientists with sub-pg/ml level measurements of low-abundance analytes in healthy or disease sera and plasma.

_**To enable scientific community to overcome challenges through high-quality services**_

_**![Client Testimonial 1](https://www.pblassaysci.com/sites/default/files/inline-images/Service%20Testimonial_1_0.jpg)**_

## Request an Assay Services Quote

### Key Features offered by **S**ingle **M**olecule **C**ounting Technology on SMCxPRO and Erenna Platforms:

-   Enables **sub-pg/ml sensitivity** for accurate measurement of low abundance biomarkers in serum, plasma or other complex matrices
    
-   Requires minimal sample dilution with a **4-Log+ dynamic range**
    
-   Provides high precision and reproducible data
    
-   Extensive analyte menu of over **30 different cytokine assays** covering several disease areas
    

Powered by SMCxPRO<sup>®</sup> & Erenna® Immunoassay Systems, MilliporeSigma Inc., Burlington, MA, USA.

![PBL Singulex Erenna shows the ability to measure low levels of IL-1 Beta in Plasma samples (Heparin, Citrate, and EDTA)](https://www.pblassaysci.com/sites/default/files/inline-images/il-1_beta_plasma_0.png)

**Figure 1.** Median levels of IL-1b (Interleukin 1 Beta) in Plasma Samples (Heparin, Citrate and EDTA)

**2 Citations:**

1.  Passeron, T. _et al.,_ (2023), "A Phase **IIIb**, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplanter Psoriasis (G-PLUS)", _Dermatologic Therapy_, DOI: 10.1155/2023/9967747 ([<u><strong>link</strong></u>](https://doi.org/10.1155/2023/9967747 "(opens in a new window)"))
  
3.  Morita, A. _et al.,_  (2022), "Effect of guselkumab on serum biomarkers in Japanese palmoplanter pustulosis patients in randomized phase 3 study", _JEADV Clinical Practice,_ DOI: 10.1002/jvc2.73 ([<u><strong>link</strong></u>](https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.73 "(opens in a new window)"))